Your browser doesn't support javascript.
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
Mercado, Noe B; Zahn, Roland; Wegmann, Frank; Loos, Carolin; Chandrashekar, Abishek; Yu, Jingyou; Liu, Jinyan; Peter, Lauren; McMahan, Katherine; Tostanoski, Lisa H; He, Xuan; Martinez, David R; Rutten, Lucy; Bos, Rinke; van Manen, Danielle; Vellinga, Jort; Custers, Jerome; Langedijk, Johannes P; Kwaks, Ted; Bakkers, Mark J G; Zuijdgeest, David; Rosendahl Huber, Sietske K; Atyeo, Caroline; Fischinger, Stephanie; Burke, John S; Feldman, Jared; Hauser, Blake M; Caradonna, Timothy M; Bondzie, Esther A; Dagotto, Gabriel; Gebre, Makda S; Hoffman, Emily; Jacob-Dolan, Catherine; Kirilova, Marinela; Li, Zhenfeng; Lin, Zijin; Mahrokhian, Shant H; Maxfield, Lori F; Nampanya, Felix; Nityanandam, Ramya; Nkolola, Joseph P; Patel, Shivani; Ventura, John D; Verrington, Kaylee; Wan, Huahua; Pessaint, Laurent; Van Ry, Alex; Blade, Kelvin; Strasbaugh, Amanda; Cabus, Mehtap.
  • Mercado NB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Zahn R; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • Wegmann F; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • Loos C; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Chandrashekar A; Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Yu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Liu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Peter L; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • McMahan K; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Tostanoski LH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • He X; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Martinez DR; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Rutten L; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Bos R; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • van Manen D; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • Vellinga J; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • Custers J; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • Langedijk JP; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • Kwaks T; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • Bakkers MJG; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • Zuijdgeest D; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • Rosendahl Huber SK; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • Atyeo C; Janssen Vaccines and Prevention BV, Leiden, The Netherlands.
  • Fischinger S; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Burke JS; Harvard Medical School, Boston, MA, USA.
  • Feldman J; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Hauser BM; Harvard Medical School, Boston, MA, USA.
  • Caradonna TM; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Bondzie EA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Dagotto G; Harvard Medical School, Boston, MA, USA.
  • Gebre MS; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Hoffman E; Harvard Medical School, Boston, MA, USA.
  • Jacob-Dolan C; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Kirilova M; Harvard Medical School, Boston, MA, USA.
  • Li Z; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Lin Z; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Mahrokhian SH; Harvard Medical School, Boston, MA, USA.
  • Maxfield LF; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Nampanya F; Harvard Medical School, Boston, MA, USA.
  • Nityanandam R; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Nkolola JP; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Patel S; Harvard Medical School, Boston, MA, USA.
  • Ventura JD; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Verrington K; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Wan H; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Pessaint L; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Van Ry A; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Blade K; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Strasbaugh A; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Cabus M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Nature ; 586(7830): 583-588, 2020 10.
Article in English | MEDLINE | ID: covidwho-690836
ABSTRACT
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1-8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. Fifty-two rhesus macaques (Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Pandemics / Betacoronavirus / Macaca mulatta Type of study: Experimental Studies / Prognostic study Topics: Vaccines / Variants Limits: Animals Language: English Journal: Nature Year: 2020 Document Type: Article Affiliation country: S41586-020-2607-z

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Pandemics / Betacoronavirus / Macaca mulatta Type of study: Experimental Studies / Prognostic study Topics: Vaccines / Variants Limits: Animals Language: English Journal: Nature Year: 2020 Document Type: Article Affiliation country: S41586-020-2607-z